comparemela.com

Latest Breaking News On - Juha punnonen - Page 2 : comparemela.com

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate . Ascendis PharmaDecember 30, 2020 GMT - TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response  - COPENHAGEN, Denmark, Dec. 30, 2020 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate the clinical program of TransCon TLR7/8 Agonist.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.